raveron injektionslösung
pierre fabre pharma gmbh - prostata von paarhufern, fe mit essigsäure/essigsäure-wasser (%-angaben) - injektionslösung - prostata von paarhufern, fe mit essigsäure/essigsäure-wasser (%-angaben) 0.9972ml
firmagon
ferring pharmaceuticals a/s - degarelix - prostata-neoplasmen - endokrine therapie - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
tookad
steba biotech s.a - padeliporfin-di-kalium - prostata-neoplasmen - antineoplastische mittel - tookad ist indiziert als monotherapie für erwachsene patienten mit zuvor unbehandeltem, einseitige, geringes risiko, adenokarzinom der prostata mit einer lebenserwartung von ≥ 10 jahren:im klinischen stadium t1c oder t2a;gleason-score ≤ 6, basierend auf hoher auflösung biopsie strategien;psa ≤ 10 ng/ml;3 positive krebs-kerne mit einer maximalen krebs core länge von 5 mm in einem kern-oder 1-2 positive krebs-kerne mit ≥ 50 % beteiligung krebs in einem kern oder einer psa-dichte ≥ 0. 15 ng/ml/cm3.
nubeqa
bayer ag - darolutamide - prostatahyperplasie neubildungen, kastration-resistentem - endokrine therapie - nubeqa is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmcrpc) who are at high risk of developing metastatic disease (see section 5. - metastatic hormone sensitive prostate cancer (mhspc) in combination with docetaxel and androgen deprivation therapy (see section 5.
cabazitaxel accord
accord healthcare s.l.u. - cabazitaxel - prostatahyperplasie neubildungen, kastration-resistentem - antineoplastische mittel - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
abiraterone accord
accord healthcare s.l.u. - abirateronacetat - prostata-neoplasmen - endokrine therapie - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone mylan
mylan ireland limited - abirateronacetat - prostata-neoplasmen - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone krka
krka, d.d., novo mesto - abirateronacetat - prostata-neoplasmen - endokrine therapie - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.
orgovyx
accord healthcare s.l.u. - relugolix - prostata-neoplasmen - endokrine therapie - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - prostata-neoplasmen - endokrine therapie - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.